GenCRISPR™ Cas9 v1.1
| Z03701 | |
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| Z03701 | |
|
|
|
|
|
|
| Ask us a question | |
The GenCRISPR™
Cas9 v1.1 can be formed
with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP
complex to perform gene editing has been shown to reduce the challenges
encountered with other CRISPR gene editing techniques such as viral and plasmid
delivery. Challenges include off-target effects, cell viability and transcription/translational
challenges. GenCRISPR™ Cas9 v1.1 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle nucleus localization signal (BPNLS) at both N-terminal and C-terminal. It has been reported that BPNLS is able to improve the gene editing efficiency. |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
| Key Features |
High knockout
efficiencies: Consistent high editing efficiency in in-vitro and in-vivo. Tag-free: No extra tag amino acid. DNA-free: No external DNA added to the system. |
|
gRNA-dependent double-stranded DNA cleavage |
| Source |
Recombinant
Cas9 with a BPNLS at both N-terminal and C-terminal expressed by E.coli |
| Species |
Streptococcus pyogenes |
| Tag |
Tag-free |
| Molecular Weight |
~160
kDa |
| Concentration |
4 mg/ml |
| Active temperature |
This
Cas9 is active at 37 °C. |
| Formulation |
Supplied as a solution of 25 mM Tris, 300 mM NaCl, 0.1
mM EDTA, 50% glycerol, pH 8.0. |
| Storage & Stability |
This product remains stable for up to 12 months at -20
°C. Avoid repeated
freeze-thaw cycles. |
| Appearance |
Clear,
colorless liquid |
| Purity |
≥ 90%
as analyzed by SDS-PAGE |
| Concentration |
4
mg/ml±10% |
| Bioactivity |
≥ 90% |
| Residual DNase |
Non-specific
DNase activity |
| Residual RNase |
Non-specific
RNase activity |
| Endotoxin Level |
≤
100 EU/mg as analyzed by gel clotting method |
| References |
1.
Liu, Xinyi, et al. "Improving editing
efficiency for the sequences with NGH PAM using xCas9-derived base
editors." Molecular Therapy-Nucleic Acids 17 (2019): 626-635. 2. Pollard, Victoria W., et al. "A novel receptor-mediated nuclear protein import pathway." Cell 86.6 (1996): 985-994. 3. Koblan, Luke W., et al. "Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction." Nature biotechnology 36.9 (2018): 843-846. 2. Pollard, Victoria W., et al. "A novel receptor-mediated nuclear protein import pathway." Cell 86.6 (1996): 985-994. 3. Koblan, Luke W., et al. "Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction." Nature biotechnology 36.9 (2018): 843-846. |